U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a bold plan to identify the cause of autism by September 2025. Speaking at a cabinet meeting with President Donald Trump, Kennedy declared a global research initiative involving hundreds of scientists to determine the source of rising autism rates, which reached 1 in 36 children by 2020, according to the CDC.
“We’ll know by September what has caused the autism epidemic and how to eliminate those exposures,” Kennedy said, hinting at environmental and artificial factors. The initiative is part of Trump’s broader “Make America Healthy Again” Commission, which is also reviewing rising childhood conditions like asthma and ADHD.
The autism community, however, responded with skepticism. Kristyn Roth of the Autism Society of America criticized the deadline and the framing of autism as an “epidemic,” warning it promotes fear and stigmatization. Experts caution that increased diagnoses are largely due to expanded diagnostic criteria and awareness, not an unknown epidemic.
Kennedy, known for promoting a disproven link between vaccines and autism, confirmed vaccines will be reviewed, along with potential environmental and lifestyle triggers. Meanwhile, a recent study has strengthened ties between prenatal diabetes and autism risk.
Controversy deepened after reports surfaced of David Geier—previously fined for unlicensed medical practices—being hired to investigate vaccine links. Lawmakers and advocacy groups fear the spread of misinformation under Kennedy’s leadership.
The National Institutes of Health and the CDC, both under Kennedy’s purview, are planning multimillion-dollar research efforts into autism causes, including vaccine-related studies. Critics argue the push may politicize science and mislead the public.
Despite widespread concern, Kennedy remains firm: “There will be no bigger news than finding the cause of autism.” Whether science can meet his deadline remains uncertain.


Iran Plans New Gulf Restricted Zone as Hormuz Tensions Push Oil Higher
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Trump Peace Envoys Meet Zelenskiy in Kyiv After Putin Talks
Trump Signs Order to Cut Routine Childhood Vaccines
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Putin Meets US Envoys in Moscow as Ukraine Peace Push Intensifies
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 



